KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ClearPoint Neuro (CLPT) Change in Accured Expenses (2018 - 2025)

Historic Change in Accured Expenses for ClearPoint Neuro (CLPT) over the last 13 years, with Q3 2025 value amounting to $693000.0.

  • ClearPoint Neuro's Change in Accured Expenses rose 710.97% to $693000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $481000.0, marking a year-over-year decrease of 7246.71%. This contributed to the annual value of $3.1 million for FY2024, which is 57842.84% up from last year.
  • Per ClearPoint Neuro's latest filing, its Change in Accured Expenses stood at $693000.0 for Q3 2025, which was up 710.97% from $938000.0 recorded in Q2 2025.
  • In the past 5 years, ClearPoint Neuro's Change in Accured Expenses registered a high of $1.7 million during Q4 2024, and its lowest value of -$2.9 million during Q1 2025.
  • Moreover, its 5-year median value for Change in Accured Expenses was $374000.0 (2023), whereas its average is $214789.5.
  • Over the last 5 years, ClearPoint Neuro's Change in Accured Expenses had its largest YoY gain of 44339.62% in 2022, and its largest YoY loss of 118148.15% in 2022.
  • ClearPoint Neuro's Change in Accured Expenses (Quarter) stood at -$133000.0 in 2021, then surged by 352.63% to $336000.0 in 2022, then increased by 11.31% to $374000.0 in 2023, then soared by 363.1% to $1.7 million in 2024, then tumbled by 59.99% to $693000.0 in 2025.
  • Its Change in Accured Expenses was $693000.0 in Q3 2025, compared to $938000.0 in Q2 2025 and -$2.9 million in Q1 2025.